Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCAGN1876 and INCMGA00012 with SRS in Recurrent Glioblastoma
NCT04225039Phase 2Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jun 2020
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of INCAGN1876, retifanlimab in glioblastoma (GBM), sponsored by University of Pennsylvania. Started Jun 2020; status: active, not recruiting.
02
Drugs
INCAGN1876retifanlimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04225039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225039.